XOMA Royalty Corporation (XOMA) fair value: what the stock is really worth
As of Jul 17, 2026: fair value of XOMA Royalty Corporation $16.99, price $40.17, upside -57.7%, quality 39 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch XOMA Royalty Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $13.82 – $45.00 · fair‑value band $9.91 – $31.84 · the $40.17 price screens above the $16.99 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow XOMA Royalty in your weekly email
Every Wednesday you see whether XOMA Royalty is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates.
Show more
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States, Switzerland, the Asia Pacific, and Australia. It has a portfolio of economic rights to future potential milestone and royalty payments associated with commercial products and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to sponsors or developers; and acquires milestone and royalty revenue streams on late-stage clinical assets and commercial assets. It has a portfolio with various assets. The company was formerly known as XOMA Corporation and changed its name to XOMA Royalty Corporation in July 2024. XOMA Royalty Corporation was incorporated in 1981 and is headquartered in Emeryville, California.
Stock analysis
XOMA Royalty Corporation (XOMA) currently trades at $40.17, while our model-based Fair Value estimate is $16.99, 57.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $83.34 per share, and 6 of the 26 models we run sit above the $40.17 price.
Bear case: the Asset-Based group reads lowest at $3.94, and 20 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $9.91 (bear) to $31.84 (bull), the price of $40.17 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
XOMA Royalty Corporation reported revenue of $52.1M in FY2025 versus $38.2M in FY2021, a compound +8.1%/yr. Reported net income was $31.7M in FY2025, compounding +19.0%/yr from FY2021.
Key figures
Market cap $722M · P/E ratio 25.6 · P/S ratio 15.6 · EPS (TTM) $1.57 · Dividend yield 0.7% · Net margin 60.8% · Return on equity 34.2% · Return on assets (EBIT) −6.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 11% below its 52-week high and 75% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −58%, XOMA screens richer than that median.
Fair Value models
Bear $9.91Fair Value $16.99Bull $31.84
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.19 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.62/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+83.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+105.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.2%
Start year 2020 (pandemic). Over 10 years: −0.6% a year
Revenue growth 40 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
’12
’13
’14
’15
’17
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+8.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+7.5%
Dividend (yield on the price)0.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.42% → 22%
⚠ Revenue per share shrinking 11.4%/yr over ~10Y (margin trend unclear) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+66.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+13.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +62.7% a year for the price and +10.6% for the forecasts.
Compare XOMA Royalty Corporation with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 629 stocks
Beats the industry median on 4/14 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Below median
Fair Value upside−57.7% · Below median
Profitability
Return on equity (TTM)34.2% · Top 25%
Return on assets1.3% · Above median
Net margin (TTM)69.6% · Top 25%
Operating margin (TTM)−3.9% · Below median
Growth and dividend
Revenue growth−22.6% · Bottom 25%
Dividend yield (TTM)0.7% · Below median
Balance sheet
Debt / equity0.93× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/E (TTM)25.6× · Cheaper than median
P/B6.95× · Priciest 25%
P/S (TTM)14.88× · Priciest 25%
P/FCF251.6× · Priciest 25%
EV/EBITDA88.7× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)0· sector 0
PAST (return on equity)100· sector 0
HEALTH (low debt)54· sector 97
DIVIDEND (yield)15· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is XOMA Royalty Corporation (XOMA) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $16.99 versus the last price from Jul 17, 2026 of $40.17, about −58% upside (overvalued).
What is the fair value of XOMA?
Our model-based fair value for XOMA Royalty Corporation is $16.99 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 17, 2026): $40.17.
What is the quality score of XOMA?
XOMA Royalty Corporation has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for XOMA Royalty Corporation (XOMA)?
Our model-based price target is the fair value of $16.99 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $9.91, optimistic scenario $31.84. It is a calculation from audited fundamentals, not an analyst target.
What is the XOMA Royalty Corporation stock forecast for 2026?
Our models put fair value at $16.99, about −58% upside versus the last price from Jul 17, 2026 of $40.17 (overvalued). Cautious scenario $9.91, optimistic scenario $31.84. The calculation is refreshed regularly with new filings.
What is the revenue of XOMA Royalty Corporation (XOMA)?
XOMA Royalty Corporation reported trailing-twelve-month revenue of about $48.6M (latest available figure, as of Sep 24, 2026).
Does XOMA Royalty Corporation pay a dividend?
XOMA Royalty Corporation currently shows a dividend yield of about 0.73% relative to its recent price (as of Sep 24, 2026).
What growth is priced into XOMA Royalty Corporation (XOMA)?
For today's price to be fair in a discounted-cash-flow model, XOMA Royalty Corporation would have to grow free cash flow by +66.6 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +12.2 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of XOMA use?
Our models discount XOMA Royalty Corporation at 10.9 %: a base by market capitalisation (small), damped by beta 0.87, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For XOMA Royalty Corporation that is +66.6 % per year a year over ten years, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has XOMA Royalty Corporation (XOMA) delivered so far?
Over the past 5 years revenue at XOMA Royalty Corporation grew +12.2 % a year. The price currently implies +66.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of XOMA Royalty Corporation (XOMA) growing?
The median revenue growth in the sector is +5.0 % a year. That is the yardstick for the growth priced into XOMA Royalty Corporation (+66.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of XOMA Royalty Corporation (XOMA)?
The free-cash-flow yield on the price is 0.40 %: that much free cash flow XOMA Royalty Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of XOMA Royalty Corporation (XOMA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For XOMA Royalty Corporation it is $16.99 per share (as of Sep 24, 2026), against a price of $40.17. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is XOMA Royalty Corporation stock overvalued or undervalued in 2026?
As of Sep 24, 2026, XOMA trades above its calculated fair value: price $40.17, fair value $16.99, a gap of about −58% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of XOMA?
No. The price is what the market pays today ($40.17); the fair value is what the company's own numbers justify ($16.99). For XOMA Royalty Corporation the two are $23.18 per share apart. That gap is exactly why we show both numbers side by side.
How much is XOMA Royalty Corporation worth?
The market values XOMA Royalty Corporation at about $722M (market capitalisation, as of Sep 24, 2026). Per share that is $40.17; our models calculate a fair value of $16.99 per share.
What do the bullish and bearish scenarios say about XOMA?
Our models span a range for XOMA Royalty Corporation: cautious scenario $9.91, base $16.99, optimistic $31.84 per share (as of Sep 24, 2026, price $40.17). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of XOMA?
XOMA Royalty Corporation trades at a price-to-earnings ratio of 25.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $16.99 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 27.5 (reported for FY2025: 22.9). Other multiples: P/B 7.0, P/S 14.9, EV/EBITDA 88.7.
How solid is the balance sheet of XOMA Royalty Corporation (XOMA)?
Balance-sheet figures for XOMA Royalty Corporation (as of Sep 24, 2026): return on equity 34.2%, debt of 0.93 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is XOMA from its 52-week high?
XOMA Royalty Corporation trades at $40.17, about 11% below its 52-week high of $45.00 and 75% above the low of $22.89 (as of Jul 17, 2026). Distance from the high says nothing about value: that is what the fair value of $16.99 is for.
Which stocks are comparable to XOMA Royalty Corporation?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is XOMA Royalty Corporation stock attractive at the current price?
The data as of Sep 24, 2026: price $40.17, calculated fair value $16.99 (−58%), Quality Score 39/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of XOMA calculated?
We run XOMA Royalty Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $16.99, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. XOMA Royalty Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of XOMA Royalty Corporation (XOMA)?
The latest price we hold is from Jul 17, 2026 and stands at $40.17. Our model-based fair value is $16.99, about −58% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with XOMA Royalty Corporation right now?
The price sits above even our optimistic bull case ($31.84). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide ($9.91 to $31.84). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Key figures of XOMA Royalty Corporation
How large is the market capitalisation of XOMA Royalty Corporation (XOMA)?
The market capitalisation of XOMA Royalty Corporation is $722M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of XOMA Royalty Corporation (XOMA)?
The price-to-sales ratio of XOMA Royalty Corporation is 15.6 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of XOMA Royalty Corporation (XOMA)?
Earnings per share at XOMA Royalty Corporation are $1.57 (price ÷ EPS = P/E 25.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of XOMA Royalty Corporation (XOMA)?
The dividend yield of XOMA Royalty Corporation is 0.7% (payout 18.8%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of XOMA Royalty Corporation (XOMA)?
The net margin of XOMA Royalty Corporation is 60.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of XOMA Royalty Corporation (XOMA)?
The return on equity (ROE) of XOMA Royalty Corporation is 34.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of XOMA Royalty Corporation (XOMA)?
On an EBIT basis the return on assets of XOMA Royalty Corporation is −6.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of XOMA Royalty Corporation (XOMA)?
The operating margin of XOMA Royalty Corporation is −3.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at XOMA Royalty Corporation (XOMA)?
Revenue at XOMA Royalty Corporation is growing −22.6% versus a year earlier (3y avg +105%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at XOMA Royalty Corporation (XOMA)?
Earnings per share at XOMA Royalty Corporation are growing +208% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does XOMA Royalty Corporation (XOMA) carry?
The net debt of XOMA Royalty Corporation is $48.6M (fiscal year 2025, ≈ 16.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch XOMA Royalty Corporation in the live analysis
One click puts XOMA Royalty Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Broad data
Sep 24, 2026